Abstract

Objective To determine the efficacy of compound Tripterygium wilfordii as an adjunctive therapy in rheumatoid arthritis (RA) , and its effects on serum fractalkine (FKN/CX3CL1) , erythrocyte sedimentation rate (ESR) and rheumatoid factors (RFs) . Methods A total of 102 RA patients admitted to our hospital between January 2017 and March 2018 were included in the study. According to different treatment methods, all patients were divided into the control group and study group. The control group was treated with conventional therapy. The study group was treated with conventional therapy plus adjunctive therapy with compound Tripterygium wilfordii. The clinical efficacy in the two groups after the treatment were analyzed. Results There were no statistically significant differences in the morning stiffness time, mean grip strength and VAS score at baseline between the two groups (all P>0.05) . After the treatment, the morning stiffness time was shorter, the mean grip strength was higher than that in the control group, and the VAS score was lower, in the study group compared with the control group (all P 0.05) . After the treatment, the positive rate of AKA in the study group was lower than that in the control group, whereas the SF-36 score in the study group was higher than that in the control group, with statistically significant differences (both P 0.05) . After the treatment, the levels of f FKN/CX3CL1, ESR, RF and COX-2 in the study group were lower than those in the control group, with statistically significant differences (all P<0.05) . Conclusion Adjunctive therapy with compound Tripterygium wilfordii for RA may relieve clinical symptoms, reduce levels of FKN/CX3CL1, ESR and RF, and improve quality of life. Key words: Compound Tripterygium wilfordii; Rheumatoid arthritis; Serum fractalkine; Erythrocyte sedimentation rate; Quality of life

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call